The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy.

The approval gives Novo Nordisk a head start over chief rival Eli Lilly, which is racing to launch its own obesity pill.

It marks a first in this new era of weight-loss medications with Wegovy being the only so far to gain approval for a pill version of their shot.